Table 1

Demographic and clinical manifestations of patients with systemic lupus erythematosus (SLE) at enrolment visit

Number of patients1206
Gender (n (%))
 Female1080 (89.6)
 Male126 (10.4)
Age (years) (mean ± SD) at enrolment34.5±13.2
Ethnicity (%)
 Caucasian47.4
 Hispanic16.5
 Asian16.5
 Black15.6
 Other3.9
Region (%)
 Canada22.2
 USA, Mexico41.4
 Europe25.1
 Asia11.3
Single/married/other (%)46.6/40.8/12.6
Post-secondary education (%)62.1
Disease duration (months) (mean±SD)5.4 ± 4.2
Number of ACR criteria (mean±SD)4.5 ±1.01
Cumulative ACR manifestations (n (%))
 Malar rash501 (41.5)
 Discoid rash174 (14.4)
 Photosensitivity434 (36.0)
 Oral/nasopharyngeal ulcers539 (44.7)
 Serositis336 (27.9)
 Arthritis886 (73.5)
 Renal disorder346 (28.7)
 Neurological disorder71 (5.9)
 Haematological disorder742 (61.5)
 Immunological disorder923 (76.5)
 Antinuclear antibody1158 (96.0)
SLEDAI score (mean±SD)5.4 ± 5.5
SLICC/ACR score (mean±SD)0.3 ± 0.8
Medications (%)
 Corticosteroids835 (69.2)
 Antimalarial agents744 (61.7)
 Immunosuppressant agents471 (39.1)
 Aspirin170 (14.1)
 Antidepressants105 (8.7)
 Anticonvulsants48 (4.0)
 Warfarin59 (4.9)
 Antipsychotics7 (0.6)
  • ACR, American College of Rheumatology; SLEDAI, SLE Disease Activity Index; SLICC, Systemic Lupus International Collaborating Clinics.